Original language | English (US) |
---|---|
Pages (from-to) | E318-E321 |
Journal | Haematologica |
Volume | 105 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2020 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haematologica, Vol. 105, No. 6, 01.06.2020, p. E318-E321.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma
AU - Araf, Shamzah
AU - Korfi, Koorosh
AU - Bewicke-Copley, Findlay
AU - Wang, Jun
AU - Cogliatti, Sergio
AU - Kumar, Emil
AU - Forrer, Flavio
AU - Barrington, Sally F.
AU - Graham, Trevor A.
AU - Scott, David W.
AU - Rimsza, Lisa M.
AU - Davies, Andrew
AU - Johnson, Peter
AU - Okosun, Jessica
AU - Fitzgibbon, Jude
AU - Fehr, Martin
N1 - Funding Information: 1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK; 2Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK; 3Institute of Pathology, Cantonal Hospital St Gallen, St Gallen, Switzerland; 4Department of Nuclear Medicine, Cantonal Hospital St Gallen, St Gallen, Switzerland; 5King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK; 6Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK; 7Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada; 8Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA; 9Cancer Research UK Centre, University of Southampton, Southampton, UK and 10Clinic for Medical Oncology and Haematology, Cantonal Hospital St Gallen, St Gallen, Switzerland Funding: this work was supported by grants from Cancer Research UK (15968 awarded to JF, Clinical Research Fellowship awarded to SA) and Bloodwise through funding of the Precision Medicine for Aggressive Lymphoma (PMAL) consortium (15002). SFB acknowledges support from the National Institute for Health Research and Social Care (NIHR) [RP-2-16-07-001]. King’s College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC in association with the MRC and Department of Health and Social Care (England). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Correspondence: SHAMZAH ARAF - [email protected] JUDE FITZGIBBON - [email protected] doi:10.3324/haematol.2019.242206 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.
PY - 2020/6/1
Y1 - 2020/6/1
UR - http://www.scopus.com/inward/record.url?scp=85085677964&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085677964&partnerID=8YFLogxK
U2 - 10.3324/haematol.2019.242206
DO - 10.3324/haematol.2019.242206
M3 - Letter
C2 - 32273479
AN - SCOPUS:85085677964
SN - 0390-6078
VL - 105
SP - E318-E321
JO - Haematologica
JF - Haematologica
IS - 6
ER -